- Home
- CIGL vs LPTX Comparison
CIGL vs LPTX Comparison
Compare CIGL & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- LPTX
- Stock Information
- Founded
- CIGL 1997
- LPTX 2011
- Country
- CIGL Singapore
- LPTX United States
- Employees
- CIGL N/A
- LPTX N/A
- Industry
- CIGL Diversified Commercial Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIGL Consumer Discretionary
- LPTX Health Care
- Exchange
- CIGL Nasdaq
- LPTX Nasdaq
- Market Cap
- CIGL 145.9M
- LPTX 119.6M
- IPO Year
- CIGL 2025
- LPTX N/A
- Fundamental
- Price
- CIGL $6.09
- LPTX $0.37
- Analyst Decision
- CIGL
- LPTX Buy
- Analyst Count
- CIGL 0
- LPTX 2
- Target Price
- CIGL N/A
- LPTX $8.00
- AVG Volume (30 Days)
- CIGL 34.8K
- LPTX 283.3K
- Earning Date
- CIGL 01-01-0001
- LPTX 05-13-2025
- Dividend Yield
- CIGL N/A
- LPTX N/A
- EPS Growth
- CIGL N/A
- LPTX N/A
- EPS
- CIGL N/A
- LPTX N/A
- Revenue
- CIGL $10,490,668.00
- LPTX N/A
- Revenue This Year
- CIGL N/A
- LPTX N/A
- Revenue Next Year
- CIGL N/A
- LPTX N/A
- P/E Ratio
- CIGL N/A
- LPTX N/A
- Revenue Growth
- CIGL N/A
- LPTX N/A
- 52 Week Low
- CIGL $3.63
- LPTX $0.22
- 52 Week High
- CIGL $7.27
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- LPTX 48.92
- Support Level
- CIGL N/A
- LPTX $0.36
- Resistance Level
- CIGL N/A
- LPTX $0.40
- Average True Range (ATR)
- CIGL 0.00
- LPTX 0.04
- MACD
- CIGL 0.00
- LPTX 0.00
- Stochastic Oscillator
- CIGL 0.00
- LPTX 54.63
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .